Early Lopinavir/ritonavir does not reduce mortality in COVID-19 patients: Results of a large multicenter study

被引：6
|
作者：
Lora-Tamayo, Jaime [1 ]
Maestro, Guillermo [1 ]
Lalueza, Antonio [1 ]
Rubio-Rivas, Manuel [2 ]
Villarreal Paul, Gracia [3 ]
Arnalich Fernandez, Francisco [4 ]
Beato Perez, Jose Luis [5 ]
Vargas Nunez, Juan Antonio [6 ]
Llorente Barrio, Monica [7 ]
Lumbreras Bermejo, Carlos [1 ]
机构：
[1] 12 Octubre Univ Hosp, Res Inst Hosp 12 Octubre I 12 Inst, Internal Med Dept, Madrid, Spain
[2] Bellvitge Univ Hosp IDIBELL, Internal Med Dept, Lhospitalet De Llobregat, Barcelona, Spain
[3] Gregorio Maranon Univ Hosp, Internal Med Dept, Madrid, Spain
[4] La Paz Univ Hosp, Internal Med Dept, Madrid, Spain
[5] Albacete Univ Hosp Complex, Internal Med Dept, Albacete, Spain
[6] Puerta Hierro Univ Hosp, Internal Med Dept, Majadahonda, Madrid, Spain
[7] Miguel Servet Hosp, Internal Med Dept, Zaragoza, Spain
来源：
JOURNAL OF INFECTION | 2021年 / 82卷 / 06期
关键词：
D O I：
10.1016/j.jinf.2021.02.011
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
引用
收藏
页码：293 / 298
页数：6
相关论文
共 50 条
  • [21] Lopinavir/ritonavir in COVID-19 patients: maybe yes, but at what dose?
    Baldelli, Sara
    Corbellino, Mario
    Clementi, Emilio
    Cattaneo, Dario
    Gervasoni, Cristina
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2020, 75 (09) : 2704 - 2706
  • [22] Early antiviral therapy of abidol combined with lopinavir/ritonavir and recombinant interferon α-2b for patients with COVID-19 in Zhejiang: A multicenter prospective study
    Wei Runan
    Zheng Nanhong
    Jiang Xiangao
    Ma Chunlian
    Xu Xiaowei
    Liu Shourong
    Chen Yongping
    Xu Kaijin
    Gao Hainv
    Zhu Jiansheng
    Shu Qiang
    Sheng Jifang
    Zhang Xiaoqiang
    Li Minghui
    Zhang Yan
    Ma Mengjie
    Zhang Xuan
    Li Shibo
    Wang Qiujing
    Ying Lingjun
    Zhang Yongjun
    Shi Yunzhen
    Fan Lingyan
    Yu Wanjun
    Wang Huaying
    Sun Dandan
    Wang Xiaodong
    Shi Jichan
    Chen Yinghu
    Xie Xinsheng
    Chen Yunqing
    Wang Weihong
    Tong Zhaowei
    Tang Lingling
    Zhu Mengfei
    Zhang Lingjian
    Li Lanjuan
    中华临床感染病杂志, 2020, (01) : 9 - 15
  • [23] A Trial of Lopinavir-Ritonavir in Covid-19 Reply
    Cao, Bin
    Zhang, Dingyu
    Wang, Chen
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (21):
  • [24] BET 1: LOPINAVIR-RITONAVIR AND COVID-19
    Dolan, Daniel
    Ingham, Jack
    Baombe, Janos
    EMERGENCY MEDICINE JOURNAL, 2020, 37 (07) : 450 - +
  • [25] Does melatonin reduce mortality in COVID-19?
    Pilia, Eros
    Alborino, Ettore
    Covello, Remo Daniel
    ANNALS OF MEDICINE AND SURGERY, 2022, 78
  • [26] No Benefit for Lopinavir-Ritonavir in Severe COVID-19
    Slomski, Anita
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2020, 323 (20): : 1999 - 1999
  • [27] Does hydroxychloroquine reduce mortality for COVID-19?
    Gallus, Silvano
    Clavenna, Antonio
    Lugo, Alessandra
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2020, 82 : 21 - 22
  • [28] Lopinavir / ritonavir for COVID-19: A living systematic review
    Verdugo-Paiva, Francisca
    Izcovich, Ariel
    Ragusa, Martin
    Rada, Gabriel
    MEDWAVE, 2020, 20 (06):
  • [29] Stopping lopinavir/ritonavir in COVID-19 patients: duration of the drug interacting effect
    Stader, Felix
    Khoo, Saye
    Stoeckle, Marcel
    Back, David
    Hirsch, Hans H.
    Battegay, Manuel
    Marzolini, Catia
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2020, 75 (10) : 3084 - 3086
  • [30] Pharmacokinetics of Lopinavir and Ritonavir in Patients Hospitalized With Coronavirus Disease 2019 (COVID-19)
    Schoergenhofer, Christian
    Jilma, Bernd
    Stimpfl, Thomas
    Karolyi, Mario
    Zoufaly, Alexander
    ANNALS OF INTERNAL MEDICINE, 2020, 173 (08) : 670 - +
12345